SANUWAVE Announces Positive 24-Week Data from Its Pivotal Trial with dermaPACE for the Treatment of Diabetic Foot Ulcers

SANUWAVE Health, Inc. (OTC BB: SNWV), an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, today announced positive 24-week data from the Company's pivotal double-blinded, randomized Phase III, Investigational Device Exemption clinical trial comparing dermaPACE with Sham-control, when both are combined with the current standard of care for the treatment of diabetic foot ulcers. Diabetic foot ulcers are an area of significant unmet medical need and represent a $2 billion annual market in the U.S. alone.